Jack Kennedy, the editor of the Farmers Journal, is to step down from the role.

William Minchin, chief executive of the Agricultural Trust, wrote to staff on Friday evening to inform them that Mr Kennedy “has decided to step down from his position as editor” from September 30th.

The move comes days after The Irish Times reported Mr Kennedy may leave his role amid tensions with the board of the Agricultural Trust, which is the newspaper’s publisher.

Mr Kennedy “has spent 23 years with the organisation serving as both dairy editor and deputy editor of the Irish Farmers Journal, before being appointed editor of the publication in February 2023,” Mr Minchin said in the statement.

[ Editor of Irish Farmers Journal in exit talks over major boardroom riftOpens in new window ]

“In his time with the Irish Farmers Journal, Jack Kennedy was renowned for his passion and advocacy of grass based production systems, and believed strongly in the ethos of serving farmers in rural communities.”

Deputy editors Caitríona Morrissey and Adam Woods will take over editorial responsibilities for the newspaper while a process to select a new editor will commence, Agricultural Trust chairman Liam Wolfe, said.

The move comes a week after The Irish Times reported on tensions between the Agricultural Trust board and Mr Kennedy, centred on a perception at editorial level of an overreach by the board into editorial matters.

One of the key causes of the rift surrounds plans for a 15-year lease with Tullamore Farm, a 200-acre demonstration facility in Screggan, Co Offaly, owned by the Grogan family, which is thought to be losing money.

The Government has said a deal capping future US tariffs on imports of pharmaceuticals from Europe still stands, despite US president Donald Trump’s latest threats of much higher trade levies targeting the industry.

Mr Trump announced plans to hit pharmaceuticals with a 100 per cent import tax from October 1st, unless drugmakers were building new manufacturing plants in America.

Officials in Brussels and Dublin are assessing where the threat leaves a EU-US tariff deal agreed earlier this year, which limited any coming US tariffs on pharma imports to a 15 per cent cap.

In a post on his Truth Social platform, Mr Trump dropped his latest tariff bombshell, stating the White House would be introducing huge import levies on pharmaceutical products.

“Starting October 1st, 2025, we will be imposing a 100 per cent tariff on any branded or patented pharmaceutical product, unless a company IS BUILDING their pharmaceutical manufacturing plant in America,” Mr Trump wrote. “There will, therefore, be no tariff on these pharmaceutical products if construction has started.”

The US president did not state whether this 100 per cent tariff rate would apply to European trade.

[ Trump’s pharma clampdown threatens ‘dramatic’ fall in Irish corporation tax receipts – ESRIOpens in new window ]

In a statement, Tánaiste and Minister for Foreign Affairs Simon Harris stressed the transatlantic deal on tariffs remained in place.

“We will be studying the impact of this announcement, which includes a number of exemptions, together with EU colleagues,” he said.

The deal agreed by Mr Trump and European Commission president Ursula von der Leyen was “absolutely clear” that any US tariffs on pharma imports would be limited to 15 per cent, Mr Harris said.

“This remains the case and underlines again the value of the agreement,” he said.

Mr Trump’s latest salvo drew a modest reaction from investors in morning market trading on Friday. Shares in Denmark’s Novo Nordisk were down 1.5 per cent on the day, but other big pharma groups, such as the UK’s AstraZeneca and Switzerland’s Roche, were broadly flat after initial falls.

The tariff deal saw the EU agree to suck up across-the-board tariffs on future trade with the US. This was done to avoid a full-blown trade war between the two long-standing economic partners.

Officials in the European Commission, the EU’s executive arm that steers trade policy, are confident Mr Trump’s announcement does not mean the EU’s tariff deal has been binned.

A commission spokesman said commitments from the Trump administration to limit any pharma tariffs to a 15 per cent ceiling were clear.

The EU and US would “continue engaging” on the implementation of that deal, “while exploring further areas for tariff exemptions as well as wider co-operation”, the spokesman said.

Ireland is the most exposed state in the EU to tariffs on the pharma sector.

US pharma giants Pfizer, Eli Lilly, MSD and others have large manufacturing plants in the Republic, producing drugs to ship back across the Atlantic. The industry accounts for a huge portion of the State’s exports and trade with the US and contributes a sizeable amount to the corporation tax take.

Mr Trump views tariffs as a way to pressure US multinational companies to relocate manufacturing capacity and jobs to America, often singling out Ireland as a country that “stole” pharmaceutical firms from the US.

[ World economy yet to feel full force of tariffsOpens in new window ]

A situation where tariffs were introduced on medicines and pharma products would be “the worst of all worlds”, a body representing the European pharmaceutical industry said.

Nathalie Moll, head of the European Federation of Pharmaceutical Industries and Associations, said “urgent discussions” were needed to avoid tariffs on the sector. “Tariffs increase costs, disrupt supply chains and prevent patients from getting life-saving treatments,” she said.

Mr Trump also announced new tariffs on a number of other industries and products.

Imported heavy trucks will be subject to a 25 per cent duty, kitchen cabinets and bathroom vanities will be hit with a 50 per cent charge, and upholstered furniture imports are to be taxed at 30 per cent, he said.